FDA Clears Medtronic’s MiniMed Go™ Smart MDI System with 71.5% Time in Range Gains
Medtronic Diabetes received FDA 510(k) clearance for its MiniMed Go™ Smart MDI system, combining InPen™ smart insulin pen and Abbott Instinct™ sensor, with U.S. launch planned this spring. Real-world data demonstrated Time in Range improvements from 55.7% to 71.5%, indicating strong adoption potential across 15 million MDI users globally.
1. Medtronic Poised for Strategic Acquisitions with Strong Balance Sheet
At the annual JP Morgan Healthcare Conference in San Francisco, Medtronic executives announced that the company has over $20 billion in available liquidity and a debt leverage ratio below 2.5x EBITDA, giving it "significant firepower" to pursue multiple acquisitions over the next 12–18 months. CFO Karen Parkhill noted that free cash flow reached $4.3 billion in the first half of fiscal 2026, driven by robust demand in the Cardiac Rhythm & Heart Failure and Neuroscience segments. Management emphasized that targeted bolt-on deals in robotics, digital surgery and high-growth emerging-market franchises could accelerate annual revenue growth by up to 200 basis points and enhance adjusted operating margins by 100–150 basis points within two years of close.
2. Precision Neuroscience™ Partnership to Transform Intraoperative Brain Mapping
Medtronic has entered into a strategic co-development agreement with Precision Neuroscience to integrate the Layer 7™ cortical interface into its StealthStation™ surgical navigation platform. The collaboration will enable neurosurgeons to visualize real-time electrophysiological signals alongside high-resolution 3D anatomy, reducing procedure times by up to 30 percent and improving target localization accuracy by 15 percent in early pilot studies. Precision CEO Michael Mager stated that the integrated solution is expected to enter a multicenter feasibility trial in mid-2026, with a commercial launch targeted for late 2027 pending FDA clearance. Medtronic’s Neuroscience President Brett Wall projects that this platform could address a $1.2 billion global market for advanced brain mapping tools.
3. FDA Clears MiniMed Go™ Smart MDI System to Expand Diabetes Portfolio
Medtronic Diabetes secured FDA 510(k) clearance for MiniMed Go™, the first smart multiple daily injection system that combines the InPen™ smart insulin pen with Abbott’s Instinct® CGM sensor via a unified mobile app. Clinical data from a 1,800-patient real-world cohort showed Time in Range improvements from 55.7 percent to 67.2 percent when users responded to over 75 percent of missed-dose alerts within one hour. The system is cleared for patients aged 7 and older, with pediatric use down to age 2 under caregiver supervision. Medtronic expects to commence U.S. commercial rollout in spring 2026, targeting the 15 million MDI-dependent diabetes population and projecting $250 million in incremental revenue by fiscal 2028.